Evidence for antithrombotic treatment following lower extremity revascularization (LER) for
peripheral artery disease (PAD) is limited, leading to weak and conflicting guideline …

Background Anticoagulants are the main drugs used for the prevention and treatment of
thrombosis. Currently, anticoagulant drugs are primarily multitarget heparin drugs, single …

Factor (F) XI is a procoagulant zymogen that is activated by FXIIa (contact pathway) and
thrombin [1]. However, FXI-deficient animals had no evident hemostatic phenotype, and only …

Oral anticoagulants, including warfarin and direct oral anticoagulants, are the standard of
care for thrombosis prevention and treatment; however, concerns of bleeding often dictate …

Background Cardiac arrest and cardiopulmonary resuscitation (CPR) are associated with
activated coagulation and microvascular fibrin deposition with subsequent multiorgan failure …

Heart failure (HF) patients frequently present with comorbidities such as atrial fibrillation (AF)
or other cardiovascular conditions, elevating their risk of thromboembolic events …

Factor XI (FXI) deficiency is a rare bleeding disorder of unpredictable severity that correlates
poorly with FXI coagulation activity and that poses great challenges for perioperative …

Direct oral anticoagulants (DOACs) are increasingly used for treatment and prevention of
thromboembolic diseases, used in fixed dose regimens. Although their safety and efficacy …